Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster

• 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

Neurocrine Biosciences (NASDAQ:NBIX) elaborate its planned acquisition of Soleno Therapeutics connected a league telephone Monday, outlining the woody terms, the strategical rationale, and expectations for expanding the scope of Soleno’s recently launched uncommon illness medicine Vykat XR.

Chief Executive Officer Kyle Gano said Neurocrine has entered into a definitive statement to get Soleno via a currency tender connection for each outstanding shares astatine $53 per share, implying an endeavor worth of astir $2.9 billion. Gano said the transaction is not taxable to a financing information and volition beryllium funded with currency connected hand, with Neurocrine readying to “optimize our superior operation by taking connected a humble level of pre-payable debt.”

→ 3 Utility Stocks With Strong Dividends and Room to Run Higher

• Bristol Myers Squibb’s large buys: $18.1 cardinal successful 2 biotech deals

Chief Financial Officer Matt Abernethy added that the acquisition is expected to beryllium accretive, saying it volition beryllium “immediately accretive post-close successful 2026,” portion emphasizing Neurocrine is not issuing shares to money the transaction. Abernethy besides said the company’s superior deployment strategy “is not going to alteration arsenic a effect of this,” including its attack to reinvestment successful interior R&D.

Vice President of Strategy and Business Development Samir Siddhanti said Vykat XR was approved by the FDA successful March 2025 and launched successful the U.S. successful the 2nd quarter. He said the motorboat generated $190 cardinal successful 2025 revenue for Soleno, including $92 cardinal successful the 4th quarter. Siddhanti said the aboriginal show reflects doc adoption and the product’s interaction connected patients and caregivers.

→ Why Meta's "Bellwether" Legal Loss Could Open up a Can of Worms

• Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?

Siddhanti described Prader-Willi syndrome arsenic a uncommon familial neurodevelopmental upset affecting astir 10,000 radical successful the U.S., characterized by neurological, behavioral, and metabolic dysfunction. He said hyperphagia—persistent hunger that drives compulsive food-seeking behavior—is the defining, chronic, and life-threatening symptom, contributing to important quality-of-life impacts and superior comorbidities.

According to Siddhanti, Vykat XR is the “first and lone FDA-approved attraction for hyperphagia successful patients with Prader-Willi syndrome,” and Neurocrine views a important U.S. accidental fixed the defined diligent colonisation and unmet need. Gano said Neurocrine believes Vykat XR has “blockbuster potential,” citing the diligent population, unmet need, and what helium described arsenic a beardown intelligence spot estate.